Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Laboratorios Farmaceuticos Rovi's EV-to-FCF or its related term are showing as below:
MEX:ROVIN'
s EV-to-FCF Range Over the Past 10 Years
Min: -456.95 Med: 26.98 Max: 408.96
Current: 16.94
During the past 13 years, the highest EV-to-FCF of Laboratorios Farmaceuticos Rovi was 408.96. The lowest was -456.95. And the median was 26.98.
MEX:ROVIN's EV-to-FCF is ranked better than 60.88% of 565
companies
in the Drug Manufacturers industry
Industry Median: 21.83
vs MEX:ROVIN: 16.94
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Laboratorios Farmaceuticos Rovi's PE Ratio (TTM) for today is calculated as:
Laboratorios Farmaceuticos Rovi's share price for today is MXN1168.82.
Laboratorios Farmaceuticos Rovi's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN75.429.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Laboratorios Farmaceuticos Rovi EV-to-FCF Related Terms
Laboratorios Farmaceuticos Rovi EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:ROVIN vs ZTS, UTHR, VTRS: EV-to-FCF Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Laboratorios Farmaceuticos Rovi's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laboratorios Farmaceuticos Rovi EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laboratorios Farmaceuticos Rovi's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Laboratorios Farmaceuticos Rovi's EV-to-FCF falls into.
Laboratorios Farmaceuticos Rovi's current Enterprise Value is MXN59,104 Mil.
Laboratorios Farmaceuticos Rovi's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN3,675 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a EV-to-FCF of 16.08 as of Aug. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. This is 40% below median its historical median of 26.98. According to the industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #221 out of 565 companies in the Drug Manufacturers industry, placing it in the top 39.1%.
Is Laboratorios Farmaceuticos Rovi's EV-to-FCF too high?
Laboratorios Farmaceuticos Rovi's current EV-to-FCF of 16.08 is 40% below median its 10-year median of 26.98. The Drug Manufacturers industry median EV-to-FCF is 21.83. Laboratorios Farmaceuticos Rovi's value of 16.08 is 26.3% below this industry median. Based on the distribution chart, Laboratorios Farmaceuticos Rovi ranks #221 out of 565 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laboratorios Farmaceuticos Rovi has a GF Score™ of 81/100, reflecting its overall financial health beyond just this single metric.
How does Laboratorios Farmaceuticos Rovi's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laboratorios Farmaceuticos Rovi ranks #221 out of 565 companies for EV-to-FCF. This puts Laboratorios Farmaceuticos Rovi in the upper half of its industry. The industry median EV-to-FCF is 21.83. Laboratorios Farmaceuticos Rovi's value of 16.08 is 26.3% below this benchmark. While the company's 10-year median is 26.98 vs. the industry median of 21.83, Laboratorios Farmaceuticos Rovi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 21.83, based on 565 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laboratorios Farmaceuticos Rovi's current EV-to-FCF of 16.08 is 26.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Laboratorios Farmaceuticos Rovi and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 21.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laboratorios Farmaceuticos Rovi's current EV-to-FCF is 16.08, which is 40% below median its own 10-year median of 26.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laboratorios Farmaceuticos Rovi stock overvalued right now?
Laboratorios Farmaceuticos Rovi (MEX:ROVIN) has a current EV-to-FCF of 16.08. The stock's GF Value™ is MXN1,103.32, compared to a current price of MXN1,168.82 — trading 5.9% above its estimated fair value. The current EV-to-FCF is 16.08, which is 40% below median its 10-year median of 26.98 and 26.3% below the Drug Manufacturers industry median of 21.83. Laboratorios Farmaceuticos Rovi's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Laboratorios Farmaceuticos Rovi (MEX:ROVIN), the current EV-to-FCF is 16.08 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laboratorios Farmaceuticos Rovi (MEX:ROVIN) Overvalued in 2026?
Based on GuruFocus' analysis, Laboratorios Farmaceuticos Rovi stock appears to be overvalued.
The current stock price of MXN1,168.82 is trading 5.9% above its estimated GF Value™ of MXN1,103.32.
Key valuation signals for MEX:ROVIN:
EV-to-FCF: 16.08 (40% below median its 10-year median of 26.98)
GF Value™: MXN1,103.32 vs. price of MXN1,168.82 (5.9% above fair value)
Industry Position: 26.3% below the Drug Manufacturers median (#221 of 565)
No single metric tells the full story. See the MEX:ROVIN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laboratorios Farmaceuticos Rovi SA is a biotechnology company engaged in the research, development, manufacturing, and marketing of small molecule and specialty biologic drugs. The company has a diversified portfolio of products that it markets in Spain through its specialized sales force of specialist physicians, hospitals and pharmacies. Laboratorios' research and development pipeline is focused on the expansion of applications, indications, and alternative mechanisms of action for heparin-derived products. The company aims to obtain new pharmaceutical products that enable the regular administration of formulations that are administered daily in chronic and prolonged treatments. Its two segments are Manufacturing and Marketing.
81GF Score
Get the complete analysis for MEX:ROVIN
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:ROVIN has been successfully added to your 
